Clinical trial
A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-Controlled Study of Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
NCT00088179 is registered in ClinicalTrials.gov with Alexion Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-Controlled Study of Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- July 31, 2004
- Completion date
- October 31, 2005
- Enrollment
- 4,000
- Sites
- 188
Conditions
As the registry lists them; a condition with its own page is linked.